Lonza Breaks Ground on Biologics Manufacturing Facility in Singapore
Singapore (Mar. 29)-The contract manufacturing organization Lonza Group (Basel, Switzerland) and Bio*One Capital (Singapore) broke ground for their large-scale commercial mammalian cell-culture manufacturing facility at Tuas Biomedical Park in Singapore.
Singapore (Mar. 29)-The contract manufacturing organization Lonza Group (Basel, Switzerland, www.lonza.com) and Bio*One Capital (Singapore, www.bio1capital.com) broke ground for their large-scale commercial mammalian cell-culture manufacturing facility at Tuas Biomedical Park in Singapore. Bio*One Capital, the investment arm of the Singapore Economic Development Board (www.edg.gov.sg), is a biomedical sciences investment-fund management company.
The facility will be Lonza’s second large-scale mammalian manufacturing plant in Singapore and the third one globally that the company has built.
The construction of the first shell of Lonza Biologics Tuas was initiated in February 2007. The final build-out of the facility will be completed and become fully operational at the latest in 2011, in line with custom commitments, said Lonza in a company release.
The capital investment could amount to $350 million depending upon customer requests. Lonza Biologics Tuas Pte Ltd. will have up to four mammalian bioreactor trains, each with a flexible capacity of 1000–20,000 L, inclusive of purification units.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
